Kentucky House Bill Proposes Banning E-cigs Not Authorized by FDA

Regulations by 2FIRSTS.ai

Mar.11.2024

Kentucky House Bill Proposes Banning E-cigs Not Authorized by FDA

Kentucky House Bill 11 proposes stricter regulations on e-cigarette sales, requiring FDA-approved products to protect youth from potentially harmful options.

Recently, according to reports from US media WLKY, the Kentucky State House is pushing for a bill to impose stricter restrictions on the sale of e-cigarettes and e-cigarette retailers in Kentucky. Under House Bill 11, retailers can only sell smokeless nicotine products that have been certified by the US Food and Drug Administration (FDA).

A bill has been proposed to regulate e-cigarette and vaporizer products that have fruity flavors and bright packaging, which are clearly designed to appeal to teenagers. Representative Rebecca Raymer believes that many of these products are being sold on the market without approval.

Raymer stated, "The key is that it is Congress that grants the FDA the authority to regulate these products, not us, and that is a recognized provision. There is no doubt about this, but I know that the FDA's enforcement capability is very limited. Therefore, as a state, we have a duty to provide protection to the public. If we know that these goods have not been authorized by the FDA, then we cannot allow them to appear on the shelves."

HB11 has passed out of committee and is now awaiting consideration by the full House of Representatives.

References:

[1] Proposed Kentucky bill suggests e-cigs, vapes without FDA approval be pulled from shelves

Also Read:

[1] Kentucky Public Schools Move Closer to Smoking Ban Implementation

[2] Kentucky State House Proposes Stricter Regulations on E-Cigarette Sales to Minors

[3] Kentucky Schools Struggle to Prevent E-cigarette Use on Campus

#North America #United States #Legislation #E-cigarettes #Regulation #FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

BAT Malaysia Reports Q3 Results: Net Profit Plummets 89.5%, Stock Price Drops 15%

BAT Malaysia's Q3 results show a sharp 89.5% drop in net profit to RM7 million (approximately $150,000 USD), with revenue also falling to RM300 million (approximately $6.4 million USD). The company attributed the decline to new regulatory requirements, including pictorial health warnings and the retail display ban. Its stock dropped 15.25% to RM4.78 (approximately $1.02 USD).

Oct.31 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.

Nov.14 by 2FIRSTS.ai

Product | Three Power Levels + “2+10” Setup: ELFBAR JoinOne Series Launches in UK Retail

ELFBAR rolls out the JoinOne15 Classic prefilled replaceable-pod kit, now listed across multiple UK e-commerce channels (some pages marked “coming soon”). The device uses a “2 ml prefilled pod + 10 ml refill container (‘2+10’)” system, supports three power levels, and claims up to 15,000 puffs in combined use. The kit is priced at £12.99, with matching “2+10” refill pods at £7.99.